Novotech Backs GoGive1 Vaccine Campaign

Hong Kong - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, with more than 2,000 staff globally, has joined the GoGive1 campaign, where for every fully vaccinated team member a vaccine is donated to a person in a lower income country.

A recent company-wide survey showed 95% of team members have had at least 1 dose or plan to be vaccinated. 

Novotech joined the GoGive1 campaign, backed by the WHO Foundation and GAVI, as part of the company’s COVID-19 safe workplace initiative.

The Novotech workplace policy requires team members who work in the office, visit sites or travel to provide evidence that they have been fully vaccinated. 

Novotech CEO John Moller said:

“Providing a safe working environment for staff is a priority for all employers around the world, and at Novotech we have an additional duty to protect the healthcare workers and patients at the sites we visit.

Our COVID-19 vaccination policy supports our objective of reaching full vaccination across the company.  

Our approach considers local vaccine availability and rollout, and we are funding vaccinations for Team Members where there is limited government support or to accelerate the vaccination process. 

As part of this program, Novotech is donating one vaccine for every fully vaccinated team member, to a lower income country via the WHO and GAVI GoGive1 initiative.”

Novotech’s Chief People Officer, Angela Edwardson said:

“Since vaccines have become available, we have strongly encouraged our Team Members to get vaccinated. 

We have overwhelming support for our company policy that employees should be fully vaccinated on their return to the office. Meanwhile our flexible work options will also allow unvaccinated employees to work remotely as we transition. 

We look forward to welcoming teams back to the office as restrictions ease across our regions.” 

Our key initiatives

  • Novotech is funding vaccination for team members in countries that have limited government support, or to accelerate the vaccination process. 
  • Team members who work in the office, visit sites or travel will need to provide evidence that they have been fully vaccinated or have received a negative test result. 
  • Policy implementation will be phased and dependent on vaccine rollout and availability in each location 
  • Novotech’s flexible working options facilitate Team Members to receive their vaccinations during normal working hours 

Novotech’s vaccine donation and matching programs

 Novotech Backs GoGive1 Vaccine Campaign as Part of Company-wide COVID Safe Workplace Initiative

 

Go Give 1 incentive program 

https://gogiveone.org/

For every fully vaccinated team member, Novotech will donate 1 Vaccine via the GoGive1 program. GoGive1 was created by the WHO Foundation and GAVI (https://www.gavi.org/gavi-covax-amc). Novotech has the potential to contribute over 2,000 vaccinations via this program

Donation Matching Program 

In May 2021, Novotech ran a donation matching initiative, matching all employee donations to Care.org, to provide urgent funding to India during the peak of their COVID-19 outbreak.

Media contact

About Novotech Novotech-CRO.com 

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO Award, 2024 Clinical Trials Arena Award for Excellence in Business Expansion, Marketing, and Innovation,  2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice. 

For more information or to speak to an expert team member visit www.Novotech-CRO.com